Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? Data from the Dutch National Registry of Growth Hormone Treatment in Adults

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 10, 2011, Pages 3151-3159

  Van Bunderen, Christa C ^a   Van Nieuwpoort, I Caroline ^a   Arwert, Lucia I ^a   Heymans, Martijn W ^a   Franken, Anton A M ^b   Koppeschaar, Hans P F ^c   Van Der Lely, Aart J ^d   Drent, Madeleine L ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ISALA HOSPITAL   (Netherlands)

^c ALAN TURING INSTITUTE   (United Kingdom)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE;

ADULT; AGE; ARTHRALGIA; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG WITHDRAWAL; EDEMA; FEMALE; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; JOINT STIFFNESS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; MYALGIA; NETHERLANDS; ONSET AGE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE;

ADULT; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CEREBROVASCULAR DISORDERS; FEMALE; GROWTH HORMONE; HORMONE REPLACEMENT THERAPY; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; MORTALITY; NEOPLASMS; NETHERLANDS; RECOMBINANT PROTEINS; REGISTRIES; RISK FACTORS;

EID: 80053535938     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-1215     Document Type: Article

References (37)

1. De Boer H, Blok GJ, van der Veen EA 1995 Clinical aspects of growth hormone deficiency in adults. Endocr Rev 16:63-86
2. Rosén T, Bengtsson BA 1990 Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336:285-288 (Pubitemid 20229130)
3. Cuneo RC, Salomon F, McGauley GA, Sönksen PH 1992 The growth hormone deficiency syndrome in adults. Clin Endocrinol (Oxf) 37:387-397
4. Abs R, Bengtsson BA, Hernberg-Stâhl E, Monson JP, Tauber JP, Wilton P,Wüster C 1999 GHreplacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clin Endocrinol (Oxf) 50:703-713 (Pubitemid 29284503)
5. Gutiérrez LP, Kołtowska-Häggström M, Jönsson PJ, Mattsson AF, Svensson D, Westberg B, Luger A 2008 Registries as a tool in evidence- based medicine: example of KIMS (Pfizer International Metabolic Database). Pharmacoepidemiol Drug Saf 17:90-102 (Pubitemid 351187389)
6. Webb SM, Strasburger CJ,MoD, Hartman ML, Melmed S, Jung H, BlumWF,AttanasioAF2009 Changing patterns of the adult growth hormone deficiency diagnosis documented in a decade-long global surveillance database. J Clin Endocrinol Metab 94:392-399
7. Carroll PV, Christ ER, Bengtsson BA, Carlsson L, Christiansen JS, Clemmons D, Hintz R, Ho K, Laron Z, Sizonenko P, Sönksen PH, Tanaka T, Thorne M 1998 Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab 83:382-395 (Pubitemid 28496511)
8. Götherström G, Svensson J, Koranyi J, Alpsten M, Bosaeus I, Bengtsson B, Johannsson G 2001 A prospective study of 5 years of GHreplacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab 86:4657-4665 (Pubitemid 33026070)
9. Colao A, Di Somma C, Spiezia S, Savastano S, Rota F, SavanelliMC, Lombardi G 2008 Growth hormone treatment on atherosclerosis: results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency. J Clin Endocrinol Metab 93:3416-3424
10. Svensson J, Bengtsson BA, Rosén T, Odén A, Johannsson G 2004 Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab 89:3306-3312 (Pubitemid 38960692)
11. Bengtsson BA, Koppeschaar HP, Abs R, Bennmarker H, Hernberg- Ståhl E, Westberg B, Wilton P, Monson JP, Feldt-Rasmussen U, Wüster C 1999 Growth hormone replacement therapy is not associated with any increase in mortality. KIMS Study Group. J Clin Endocrinol Metab 84:4291-4292 (Pubitemid 30644233)
12. Major JM, Laughlin GA, Kritz-Silverstein D, Wingard DL, Barrett- Connor E 2010 Insulin-like growth factor-I and cancer mortality in older men. J Clin Endocrinol Metab 95:1054-1059
13. Jenkins PJ 2006 Cancers associated with acromegaly. Neuroendocrinology 83:218-223 (Pubitemid 44578875)
14. van Nieuwpoort IC, van Bunderen CC, Arwert LI, Franken AA, Koppeschaar HP, van der Lelij AJ, Twisk JW, Boers M, Drent ML 2011 Dutch National Registry of Growth Hormone Treatment in Adults: patient characteristics and diagnostic test procedures. Eur J Endocrinol 164:491-497
15. 1998 Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency. Summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab 83:379-381
16. Breslow NE, Day NE, International Agency for Research on Cancer 1987 Statistical methods in cancer research: the design and analysis of cohort studies. IARC Sci Publ 82:1-406
17. Bates AS, Van't Hoff W, Jones PJ, Clayton RN 1996 The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 81: 1169-1172 (Pubitemid 26083989)
18. Bülow B, Hagmar L, Mikoczy Z, Nordström CH, Erfurth EM 1997 Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 46:75-81 (Pubitemid 27072849)
19. Lindholm J, Nielsen EH, Bjerre P, Christiansen JS, Hagen C, Juul S, Jørgensen J, Kruse A, Laurberg P, Stochholm K 2006 Hypopituitarism and mortality in pituitary adenoma. Clin Endocrinol (Oxf) 65:51-58
20. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC, Stewart PM 2001 Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 357:425-431
21. Rosén T, Edén S, Larson G, Wilhelmsen L, Bengtsson BA 1993 Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh) 129:195-200 (Pubitemid 23295679)
22. Swerdlow AJ, HigginsCD,Adlard P, PreeceMA2002 Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet 360:273-277 (Pubitemid 34879081)
23. Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B 2010 Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab 95:167-177
24. Shevah O, LaronZ2007 Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: a preliminary report. Growth Horm IGF Res 17:54-57
25. Svensson J, Bengtsson BA 2009 Safety aspects of GH replacement. Eur J Endocrinol 161(Suppl 1):S65-S74
26. Popovic V, Mattsson AF, Gaillard RC, Wilton P, Koltowska- Häggström M, Ranke MB 2010 Serum insulin-like growth factor I (IGFI), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database). J Clin Endocrinol Metab 95:4449-4454
27. Brada M, Ashley S, Ford D, Traish D, Burchell L, Rajan B 2002 Cerebrovascular mortality in patients with pituitary adenoma. Clin Endocrinol (Oxf) 57:713-717 (Pubitemid 36962997)
28. Nielsen EH, Lindholm J, Laurberg P, Bjerre P, Christiansen JS, Hagen C, Juul S, Jørgensen J, Kruse A, Stochholm K 2007 Nonfunctioning pituitary adenoma: incidence, causes of death and quality of life in relation to pituitary function. Pituitary 10:67-73 (Pubitemid 46566176)
29. Hayes FJ, Fiad TM, McKenna TJ 1999 Gender difference in the response of growth hormone (GH)-deficient adults to GH therapy. Metabolism 48:308-313 (Pubitemid 29115991)
30. Burman P, Johansson AG, Siegbahn A, Vessby B, Karlsson FA 1997 Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab 82: 550-555 (Pubitemid 27068627)
31. Span JP, Pieters GF, Sweep CG, Hermus AR, SmalsAG2000 Gender difference in insulin-like growth factor I response to growth hormone (GH) treatment in GH-deficient adults: role of sex hormone replacement. J Clin Endocrinol Metab 85:1121-1125 (Pubitemid 32269359)
32. Elhadd TA, Abdu TA, Oxtoby J, Kennedy G, McLaren M, Neary R, Belch JJ, ClaytonRN2001 Biochemical and biophysical markers of endothelial dysfunction in adults with hypopituitarism and severe GH deficiency. J Clin Endocrinol Metab 86:4223-4232 (Pubitemid 32848539)
33. Stochholm K, Gravholt CH, Laursen T, Laurberg P, Andersen M, Kristensen LØ, Feldt-Rasmussen U, Christiansen JS, Frydenberg M, Green A 2007 Mortality andGHdeficiency: a nationwide study. Eur J Endocrinol 157:9-18
34. Bülow B, Attewell R, Hagmar L, Malmström P, Nordström CH, Erfurth EM 1998 Postoperative prognosis in craniopharyngioma with respect to cardiovascular mortality, survival, and tumor recurrence. J Clin Endocrinol Metab 83:3897-3904 (Pubitemid 28513569)
35. Holmer H, Ekman B, Björk J, Nordstöm CH, Popovic V, Siversson A, Erfurth EM 2009 Hypothalamic involvement predicts cardiovascular risk in adults with childhood onset craniopharyngioma on long-term GH therapy. Eur J Endocrinol 161:671-679
36. Murros KE, Toole JF 1989 The effect of radiation on carotid arteries. A review article. Arch Neurol 46:449-455 (Pubitemid 19099341)
37. Smith CJ, Scott SM, Wagner BM 1998 The necessary role of the autopsy in cardiovascular epidemiology. Hum Pathol 29:1469-1479 (Pubitemid 28563982)